Business Insider
My Markets Watchlist
Markets Stocks

Viatris Inc Registered Shs Stock , VTRS

8.88 +0.18 +2.01%
03:40:59 PM BTT
News Analyst Data Analyst Opinions Insider Activity Dividend Calendar

On Monday morning 06/09/2025 the Viatris Inc Registered Shs share started trading at the price of $8.77. Compared to the closing price on Friday 06/06/2025 on BTT of $8.70, this is a gain of 0.80%. There are 1.17 B shares outstanding in Viatris Inc Registered Shs, which values the company at $8.38 B.
Is Viatris stock a Buy, Sell or Hold? Viatris stock has received a consensus rating of sell. The average rating score is and is based on 2 buy ratings, 4 hold ratings, and 4 sell ratings.
What was the 52-week low for Viatris stock? The low in the last 52 weeks of Viatris stock was 6.86. According to the current price, Viatris is 129.37% away from the 52-week low.
What was the 52-week high for Viatris stock? The high in the last 52 weeks of Viatris stock was 13.55. According to the current price, Viatris is 65.50% away from the 52-week high.
What are analysts forecasts for Viatris stock? The 10 analysts offering price forecasts for Viatris have a median target of 11.10, with a high estimate of 15.00 and a low estimate of 9.00. The median estimate represents a 79.95 difference from the last price of 8.88.

Viatris Stock Snapshot

8.87
Bid
3,990.00
Bid Size
8.88
Ask
2,200.00
Ask Size
6/9/2025
Date
3:40 PM
Time
212,960.00
Volume
8.70
Prev. Close
8.77
Open
10.22 B
Market Cap in USD
1.17 B
Number of Shares
1.17 B
Total Number of Shares
8.70
Day Low
8.90
Day High
8.88
6.86
52 Week Low
13.55
52 Week High
8.88
0.48
Dividend in USD
3.86
Dividend Yield
97.45
Free Float in %
-0.53
EPS in USD
15.61
Book Value per Share in USD
1.93
Cash Flow per Share in USD

Historical Prices for Viatris

Loading..
Date Open Close Daily High Daily Low
Price change over selected period: 0% 0

Viatris Analyst Data

Total Analysts: 10
Buy Ratings: 2 Neutral Ratings: 4 Sell Ratings: 4
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 9.00 Median: 11.10 Highest: 15.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.

Viatris Analyst Opinions

  • All
  • Buy
  • Hold
  • Sell
Date Analyst Rating Price
06/06/25 Goldman Sachs
Maintained Hold $10
03/07/25 Jefferies & Company Inc.
Maintained Buy $13
03/05/25 Piper Sandler
Maintained Hold $10
02/28/25 Barclays Capital
Maintained Sell $9
02/28/25 Bank of America Merrill Lynch
Maintained Sell $10
07/19/24 Jefferies & Company Inc.
Maintained Buy $15
03/28/24 Piper Sandler
Maintained Hold $13
11/22/23 Piper Sandler
Maintained Hold $11
10/23/23 Bank of America Merrill Lynch
Downgraded to Sell $9
06/23/23 Barclays Capital
Downgraded to Sell $11

Viatris Estimates* in USD

  2025 2026 2027 2028 2029
Revenue 13,811 14,054 14,248 14,430 14,486
Dividend 0.48 0.52 0.51 - -
Dividend Yield (in %) 5.49 % 5.99 % 5.82 % - -
EPS 2.22 2.43 2.70 - -
P/E Ratio 3.92 3.59 3.23 3.84 -
EBIT 3,663 3,866 4,082 - -
EBITDA 4,038 4,157 4,435 4,559 4,604
Net Profit 2,653 2,818 2,994 - -
Net Profit Adjusted 2,653 2,818 2,994 - -
Pre-Tax Profit 3,216 3,412 3,628 - -
Pre-Tax Profit Reported 3,257 3,463 3,607 - -
EPS (Non-GAAP) ex. SOE 2.22 2.43 2.70 - -
EPS (GAAP) -2.41 0.30 0.89 - -
Gross Income 7,805 8,017 8,160 - -
Cash Flow from Investing -400 -425 -400 - -
Cash Flow from Operations 2,377 2,588 2,721 - -
Cash Flow from Financing -1,166 -1,179 -1,266 - -
Cash Flow per Share 2.12 2.51 2.85 - -
Free Cash Flow 1,959 2,014 2,321 - -
Free Cash Flow per Share 1.66 1.77 2.13 - -
Book Value per Share 14.64 15.27 16.35 - -
Net Debt 12,844 11,957 10,716 - -
Research & Development Exp. 844 865 852 - -
Capital Expenditure 382 423 412 - -
Selling, General & Admin. Exp. 3,237 3,229 3,230 - -
Shareholder’s Equity 17,474 18,765 17,869 - -
Total Assets 42,533 43,550 44,440 - -
  Previous Quarter
ending 03/31/25 		Current Quarter
ending 06/30/25 		Next Quarter
ending 09/30/25 		Current Year
ending 12/31/25 		Next Year
ending 12/31/26
Earnings Estimates
No. of Analysts - 5 5 7 7
Average Estimate - 0.554 USD 0.614 USD 2.223 USD 2.429 USD
Year Ago - -0.274 USD 0.079 USD -0.532 USD -
Publish Date - 8/11/2025 11/10/2025 - -
Revenue Estimates
No. of Analysts - 5 5 6 6
Average Estimate - 3,467 USD 3,626 USD 13,811 USD 14,054 USD
Year Ago - 3,787 USD 3,757 USD 14,710 USD -
Publish Date - 8/11/2025 11/10/2025 - -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Income Statements in Mio. USD

2024 2023 2022 2021 2020 2019 2018
Sales 14,709.70 15,381.60 16,173.50 17,855.40 11,941.20 11,501.20 11,433.90
Change of sales in % -4.37 -4.90 -9.42 49.53 3.83 0.59 -3.97
Gross profit on sales 6,224.50 6,567.80 6,688.10 6,196.00 4,437.70 4,186.60 4,120.00
Gross profit on sales change in % -5.23 -1.80 7.94 39.62 6.00 1.62 -14.70
Operating income 1,860.80 2,053.10 2,509.10 1,667.40 1,358.80 983.10 1,117.70
Operating income change in % -9.37 -18.17 50.48 22.71 38.22 -12.04 -30.70
Income before tax -623.20 202.90 2,813.20 -664.40 -721.20 154.40 298.40
Income before tax change in % - -92.79 - 7.88 - -48.26 -66.95
Income after tax -634.20 54.70 2,078.60 -1,269.10 -669.90 16.80 352.50
Income after tax change in % - -97.37 - -89.45 - -95.23 -49.35

Balance Sheet in Mio. USD

2024 2023 2022 2021 2020 2019 2018
Total liabilities 22,865.40 27,218.10 28,949.90 34,350.10 38,598.90 19,371.70 20,567.80
Long-term liabilities per share 14.31 16.19 18.29 20.23 23.23 26.74 30.98
Equity 18,635.50 20,467.40 21,072.30 20,492.70 22,954.10 11,883.80 12,167.10
Equity change in % -8.95 -2.87 2.83 -10.72 93.15 -2.33 -8.57
Balance sheet total 41,500.90 47,685.50 50,022.20 54,842.80 61,553.00 31,255.50 32,734.90
Balance sheet total change in % -12.97 -4.67 -8.79 -10.90 96.93 -4.52 -8.58

Key Data in USD

2024 2023 2022 2021 2020 2019 2018
Sales per share 12.33 12.74 13.29 14.77 19.86 22.27 22.14
P/E ratio (year end quote, basic EPS) - 239.07 6.52 - - 618.46 40.15
P/E ratio (year end quote, diluted EPS) - 239.07 6.52 - - 618.46 40.15
Dividend yield in % 3.86 4.43 4.31 2.44 0.00 0.00 0.00
Equity ratio in % 44.90 42.92 42.13 37.37 37.29 38.02 37.17
Debt ratio in % 55.10 57.08 57.87 62.63 62.71 61.98 62.83

Viatris Insider Activity

Name Date shares traded shares held Price type (sell/buy) option
Smith Scott Andrew 05/11/2025 60,000.00 292,807.00 8.94 Buy No
Le Goff Corinne 04/14/2025 855.00 42,331.00 7.48 Sell No
Le Goff Corinne 04/14/2025 19,023.00 41,418.00 7.48 Sell No
Le Goff Corinne 04/14/2025 1,768.00 43,186.00 n/a Buy No
Le Goff Corinne 04/14/2025 39,344.00 60,441.00 n/a Buy No
Malik Rajiv 03/03/2025 339,153.00 1,068,262.00 9.37 Sell No
Malik Rajiv 03/03/2025 4,768.00 608,127.00 9.37 Sell No
Malik Rajiv 03/03/2025 35,816.00 601,933.00 9.37 Sell No
Groothuis Leo Frans 03/03/2025 50.00 39,907.00 9.37 Sell No
Groothuis Leo Frans 03/03/2025 1,166.00 39,184.00 9.37 Sell No
Le Goff Corinne 03/03/2025 521.00 21,097.00 9.37 Sell No
Le Goff Corinne 03/03/2025 16,276.00 20,445.00 9.37 Sell No
Campbell Paul 03/03/2025 74,110.00 254,140.00 9.37 Sell No
Campbell Paul 03/03/2025 7,827.00 147,651.00 9.37 Sell No
Campbell Paul 03/03/2025 319.00 159,012.00 9.37 Sell No
Campbell Paul 03/03/2025 7,493.00 158,604.00 9.37 Sell No
Campbell Paul 03/03/2025 1,042.00 148,988.00 9.37 Sell No
Roman Brian 03/03/2025 71,145.00 193,916.00 9.37 Sell No
Roman Brian 03/03/2025 435.00 102,593.00 9.37 Sell No
Roman Brian 03/03/2025 10,231.00 102,036.00 9.37 Sell No
Roman Brian 03/03/2025 1,001.00 88,905.00 9.37 Sell No
Roman Brian 03/03/2025 7,514.00 87,622.00 9.37 Sell No
Smith Scott Andrew 03/03/2025 1,546.00 232,807.00 9.37 Sell No
Smith Scott Andrew 03/03/2025 36,400.00 230,425.00 9.37 Sell No
Mistras Theodora 03/03/2025 732.00 25,180.00 9.37 Sell No

Viatris Dividend Calendar

Date Name Dividend *yield Currency
2024 Viatris Inc Registered Shs 0.48 3.86 USD
2023 Viatris Inc Registered Shs 0.48 4.43 USD
2022 Viatris Inc Registered Shs 0.48 4.31 USD
2021 Viatris Inc Registered Shs 0.33 2.44 USD
2020 Viatris Inc Registered Shs 0.00 0.00 USD
2019 Viatris Inc Registered Shs 0.00 0.00 USD
2018 Viatris Inc Registered Shs 0.00 0.00 USD
2017 Viatris Inc Registered Shs 0.00 0.00 USD
2016 Viatris Inc Registered Shs 0.00 0.00 USD
2015 Viatris Inc Registered Shs 0.00 0.00 USD
2014 Viatris Inc Registered Shs 0.00 0.00 USD
2013 Viatris Inc Registered Shs 0.00 0.00 USD
2012 Viatris Inc Registered Shs 0.00 0.00 USD
2011 Viatris Inc Registered Shs 0.00 0.00 USD
2010 Viatris Inc Registered Shs 0.00 0.00 USD
2009 Viatris Inc Registered Shs 0.00 0.00 USD
*Yield of the Respective Date

Viatris Calendar

Event Estimate Info Date
Earnings Report 0.554 USD Q2 2025 Earnings Release 08/11/2025
Earnings Report 0.614 USD Q3 2025 Earnings Release 11/10/2025
Earnings Report 0.553 USD Q4 2025 Earnings Release 03/02/2026
Earnings Report 0.535 USD Q1 2026 Earnings Release 05/11/2026

Viatris Past Events

Event Actual EPS Info Date
Earnings Report -2.550 USD Q1 2025 Earnings Release 05/08/2025
Earnings Report -0.430 USD Q4 2024 Earnings Release 02/27/2025
Annual General Meeting 0.050 USD Annual General Meeting 12/06/2024
Earnings Report 0.080 USD Q3 2024 Earnings Release 11/07/2024
Earnings Report -0.270 USD Q2 2024 Earnings Release 08/08/2024
Earnings Report 0.090 USD Q1 2024 Earnings Release 05/09/2024
Earnings Report -0.640 USD Q4 2023 Earnings Release 02/28/2024
Annual General Meeting 1.710 USD Annual General Meeting 12/15/2023
Earnings Report 0.270 USD Q3 2023 Earnings Release 11/07/2023
Earnings Report 0.220 USD Q2 2023 Earnings Release 08/07/2023
Earnings Report 0.190 USD Q1 2023 Earnings Release 05/08/2023
Earnings Report 0.830 USD Q4 2022 Earnings Release 02/27/2023
Annual General Meeting -1.050 USD Annual General Meeting 12/09/2022
Earnings Report 0.290 USD Q3 2022 Earnings Release 11/07/2022
Earnings Report 0.260 USD Q2 2022 Earnings Release 08/08/2022
Earnings Report 0.330 USD Q1 2022 Earnings Release 05/09/2022
Earnings Report -0.220 USD Q4 2021 Earnings Release 02/28/2022
Annual General Meeting -1.110 USD Annual General Meeting 12/10/2021

Viatris Profile

Viatris, Inc. is a global healthcare company, which engages in the provision of healthcare and pharmaceutical products. It provides medicines and treatments in various therapeutic areas such as cardiovascular, oncology, dermatology, eye care, gastroenterology, immunology, and women's healthcare. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment consists of operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan, and Hong Kong. The JANZ segment covers operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses operations in developing markets and emerging economies including in Asia, the Middle East, South and Central America, Africa, and Eastern Europe.

Moody’s Daily Credit Risk Score

Risk
  • Low
  • Medium
  • High
7
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

Viatris Management

Name Job
Melina E. Higgins Chairman
Robert J. Coury Chairman-Emeritus
Paul B. Campbell Chief Accounting Officer & Controller
Anil Amin Chief Business Development Officer
Corinne Le Goff Chief Commercial Officer
David Bayles Chief Compliance Officer
Scott Andrew Smith Chief Executive Officer & Director
Theodora Mistras Chief Financial Officer
Ramkumar V. Rayapureddy Chief Information Officer
Brian S. Roman Chief Legal Officer
Abhijit Barve Chief Medical Officer
Andrew Enrietti Chief People Officer
Philippe Martin Chief Research & Development Officer
Hemanth J. Varghese Chief Strategy Officer
Kristin DiBartolomeo Chief of Staff
Rajiv Malik Director
Arun Narayan Head-Commercial Development
Lara Ramsburg Head-Corporate Affairs
William Szablewski Head-Investor Relations
Elisha Wade Finney Independent Director
Harry A. Korman Independent Director
James Marshall Kilts Independent Director
JoEllen Lyons Dillon Independent Director
Leo Groothuis Independent Director
Richard A. Mark Independent Director
Rogério Vivaldi Coelho Independent Director
Wyllie Don Cornwell Independent Director
Frank A. D'Amelio Independent Director
Michael E. Severino Independent Director
Burt Park Secretary & Chief Governance Counsel
Mark W. Parrish Vice Chairman